Business
Aptamer Announces New Data at ASGCT
Aptamer Announces New Data at ASGCT.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n15 May 2025\n \nAptamer Group plc\n \n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nAptamer Announces New Data at ASGCT\nOptimer delivery vehicle supports expansion across high-value fibrotic indications\n \nAptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces new data on its Optimer therapeutic delivery vehicle for liver fibrosis. The data, developed through Aptamer's internal programme and in collaboration with AstraZeneca, highlight the delivery platform's potential for broad therapeutic application.\n \nThe latest results presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025) show the Optimer targets fibrosis in multiple tissue types and is compatible with mouse and rat animal models, which makes the transition to preclinical animal studies a simpler and faster next step.\n \nRecent in-house studies have shown that the Optimer effectively targets fibrosis in the liver as well as the kidney, skin, lung, and heart. These findings position the asset as a highly adaptable therapeutic delivery system with broad applicability across fibrotic diseases.\n \nThis represents a significant step forward in unlocking multi-billion-dollar opportunities in areas of high unmet medical need. The delivery vehicle had previously shown the ability to deliver three different siRNA molecules, demonstrating compatibility with different therapeutic cargos. The ability to combine different therapeutic cargos with targeting to different tissues means this asset could act as a platform for the development of a range of precision therapies.\n \nDr Arron Tolley, Chief Executive Officer of Aptamer Group, said: \"These results broaden the scope of Aptamer's internal development programme, indicating our asset could address a broad range of disease areas. While fibrotic liver disease remains a major focus due to its large market size and limited treatment options, the potential to expand into pulmonary, renal, cardiac, and dermal fibrosis greatly increases the commercial scope of this delivery system. \n \n\"With the market for liver fibrosis treatments set to grow at a compound annual growth rate of 24% through 2035, ...